Correlation Analysis Of Psoriasis Vulgaris Combined With Metabolic Diseases And The Effect Of Secukinumab On Metabolic Indexes

Objective To observe the prevalence of metabolic syndrome,hyperuricemia and nonalcoholic fatty liver disease in patients with psoriasis vulgaris.To investigate the correlation between the severity of the disease and metabolic syndrome.To analyze the clinical characteristics of psoriasis vulgaris patients with metabolic syndrome,and to clarify the changes of metabolic indexes in patients with psoriasis before and after secukinumab treatment.Methods Electronic medical records of patients with psoriasis attending the dermatology department of our hospital were collected(from September 2021 to December 2022).Final screening of 195 patients with psoriasis vulgaris with complete laboratory indicators.Selected healthy individuals from the physical examination center at the same time period,matched according to gender,age,and body mass index 1:2,and included in the 390 control group.The prevalence of metabolic syndrome,hyperuricemia,and nonalcoholic fatty liver disease was compared between the two groups.The case groups were divided into mild and severe groups according to the severity of psoriasis.To compare the prevalence of combined metabolic syndrome and analyze related clinical indicators in patients with mild and severe psoriasis.Univariate analysis of gender,age and duration of disease was performed in patients with common psoriasis with concomitant metabolic syndrome.Finally,psoriasis patients treated with secukinumab were selected,and their metabolic indexes before and after treatment were analyzed.Results 1.There were 32 patients(16.41%)with metabolic syndrome in the 195 case group and 36 patients(9.23%)with metabolic syndrome in the 390 control group,with statistically significant differences(P<0.05).The prevalence of hypertension,diabetes mellitus,dyslipidemia,obesity,hyperuricemia,and nonalcoholic fatty liver disease in patients with psoriasis were 18.46%,14.87%,42.05%,38.46%,38.97%,36.92%,and 12.31%,8.46%,26.67%,29.93%,27.69%,27.44% in the control group,respectively,with statistically significant differences(P<0.05).2.The prevalence of metabolic syndrome was 18.57% in the mild group and 15.20% in the severe group of patients with psoriasis vulgaris,respectively.The differences in the prevalence of metabolic syndrome,hypertension,diabetes,dyslipidemia,obesity and metabolic syndrome by age between the mild and senere groups were not statistically significant(P>0.05).3.The prevalence of hyperuricemia and nonalcoholic fatty liver disease in psoriasis vulgaris with metabolic syndrome group was higher than that in the non metabolic syndrome group,and the differences were statistically significant(P<0.05).4.The differences in body mass index,systolic blood pressure,diastolic blood pressure,fasting glucose,triglycerides,cholesterol,LDL,platelet volume distribution width and creatinine levels between the light and heavy groups were not statistically significant(P>0.05),while uric acid,lipoprotein(a),white blood cell count,neutrophil percentage,platelet count and C-reactive protein were significantly higher in the heavy group compared to the light group,and the differences were statistically significant(P<0.05).5.Metabolic syndrome associated with psoriasis vulgaris was associated with age,age of onset,body mass index,and smoking(P<0.05).6.The cholesterol,low-density lipoprotein and uric acid levels in psoriasis patients treated with secukinumab for 24 weeks were significantly lower than that without secukinumab treatment(P<0.05),and the levels of the other indexes before and after treatment were not statistically different(P>0.05).Conclusions The prevalence of metabolic syndrome,hypertension,diabetes mellitus,dyslipidemia,obesity,hyperuricemia,and nonalcoholic fatty liver disease was higher in patients with psoriasis vulgaris than in the healthy population;there was no significant correlation between the severity of psoriasis and the prevalence of metabolic syndrome,hypertension,diabetes mellitus,dyslipidemia,and obesity;Combined metabolic syndrome in psoriasis vulgaris may be associated with age,age of onset,body mass index and smoking history;Secukinumab may improve related metabolic indicators in patients with psoriasis.Appropriate screening of metabolic markers and related health education is recommended in the treatment of psoriasis.